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S U M M A R Y
Objectives: Studies have been done that have focused on the efﬁcacy of bacillus Calmette–Gue´rin (BCG)
vaccination in the prevention of cases of childhood tuberculous meningitis (TBM). However the efﬁcacy
of the vaccination in the prevention of mortality has not been sufﬁciently evaluated. This study aimed to
determine the main features of TBM cases in childhood and to evaluate the factors related to mortality,
proving the protective effect of BCG vaccination in childhood TBM.
Methods: In a retrospective approach, all consecutive cases of TBM in children that occurred between
1997 and 2005, at Dicle University Hospital, were studied. The following data were evaluated:
demographic aspects, admission symptoms, radiology and laboratory ﬁndings, BCG vaccination status,
tuberculin skin test (TST) positivity, and mortality rates.
Results: In total, 172 cases of childhood TBM were evaluated (mean age 53.3  55.7 months; 109 boys
(63.4%)). The majority of these cases (70.4%) had typical TBM symptoms on admission. BCG vaccination data
were available for 152 (88.4%) cases and 29 of them (19.1%) were positive. The TST was performed for 143
patients (83.1%) and 28 (19.6%) were found positive. Hydrocephalus was identiﬁed in 118 patients (68.6%) on
computed tomography examination. A shunt was placed in 79 cases (45.9%). In total, 24 patients (14.0%) died
in the hospital. TST negativity was a signiﬁcant factor for mortality (p = 0.012). BCG positivity was found to be
a preventive factor from mortality (p = 0.05).
Conclusions: BCG vaccination is effective in the prevention of TBM-associated mortality in childhood.
TST negativity may be a sign of a poor prognosis in TBM cases.
 2013 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious
Diseases. 
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Although the incidence of tuberculous meningitis (TBM) has
been decreasing in Turkey, the mortality and morbidity rates are
still considerably high. Despite remarkable developments in
diagnosing TBM, this clinical form of tuberculosis (TB) continues
to be one of the most severe clinical manifestations of the disease
with a high mortality rate. According to some studies, TBM
accounts for about 10% of extrapulmonary cases of TB and about 1%
of all TB cases. TBM may develop at any age, but its effects on
infants and children are the most damaging. In general, the       
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http://dx.doi.org/10.1016/j.ijid.2013.10.001incidence of TBM is higher among children than adults; children
aged less than 60 months are more commonly affected than
adults.1
In the early stages of TBM, clinical ﬁndings may be non-speciﬁc
and the symptoms subtle. During this period, the symptoms of
TBM may mimic those of other diseases. In previous studies,
almost all fatal cases were diagnosed in stages II and III.2 Despite
notable developments in bacteriological, immunobiological, and
molecular techniques in the diagnosis of TB, treatment decisions in
low-income countries are based mainly on clinical parameters.
Similarly, the prediction of the prognosis is difﬁcult in these cases.
Previous studies have focused on the efﬁcacy of bacillus Calmette–
Gue´rin (BCG) in the prevention of the severe forms of TB or the
neurological sequelae of TBM. Several studies have indicated that
the BCG vaccination is one of the best preventive measures for TBM
in childhood.3 A study estimated that BCG vaccination prevented
approximately 29 729 cases of TBM and 11 486 cases of miliary TB
in the world in the year 2002.4ociety for Infectious Diseases. Open access under CC BY-NC-ND license.
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been vaccinated previously. These reports indicate that the
prevention of TBM is not absolute. Also, there has been no study
focusing only on the efﬁcacy of BCG on mortality in TBM cases. This
study aimed to describe the main features of TBM in childhood and
to evaluate the factors related to mortality in TBM. The study
focused on the efﬁcacy of BCG and tuberculin skin test (TST)
positivity with regard to mortality.
2. Materials and methods
This observational study was carried out in the Department of
Pediatrics, Dicle University Hospital, Diyarbakir, Turkey, between
January 1997 and July 2005. All children included in the study were
aged between 1 and 180 months and had been admitted with the
diagnosis of TBM. The data collected from the patient records
included demographic aspects, household contact with TB cases,
TB history, area of residence (urban or rural), admission symptoms,
radiology and laboratory ﬁndings, duration of hospitalization, and
outcome (alive or dead).
At the time of admission, a complete physical examination was
performed on each patient. The staging of TBM in these children
and their level of consciousness were assessed using the Medical
Research Council guidelines.3 The following investigations were
performed for all patients: a complete blood count, liver function
tests, basic biochemical tests, cerebrospinal ﬂuid (CSF) analysis for
protein, glucose, cell count (total and differential), bacteriology for
tuberculous, pyogenic, and fungal organisms, acid-fast bacillus
(AFB) staining and culture from fasting gastric juice, TST, chest X-
ray, and cranial computed tomography (CT). Children who were
infected with HIV were excluded from the study.
The diagnosis of TBM was based on CSF pleocytosis (>50  106
cells/l) with one or more of the following: Mycobacterium
tuberculosis isolation from CSF culture; positive AFB staining from
a CSF sample; positive fasting gastric juice M. tuberculosis culture
or AFB smear; or positive tuberculin skin test (TST) with clinical
evidence of TBM, including CT ﬁndings and/or close contact with a
known/suspected case of TB.1–5 The Mantoux TST consists of an
intradermal injection of 0.1 ml, which contains 5 tuberculin units.
A positive TST was deﬁned as follows: >15 mm in children aged >4
years without any risk factors;1 >10 mm in children younger than
4 years of age with risk factors (without close contact with aTable 1
Epidemiological aspects of tuberculous meningitis cases
All patients
n (%)
1–24 months
n (%)
Gender, male 109 (63.4) 41 (23.8) 
Area of residence, rural 81 (47.1) 31 (18.0) 
TST
Positive 28 (16.3) 13 (7.6) 
Negative 115 (66.9) 39 (22.7) 
Absent 29 (16.9) 16 (9.3) 
BCG
Positive 29 (16.9) 9 (5.2) 
Negative 123 (71.5) 49 (28.5) 
Absent 20 (11.6) 10 (5.8) 
Household contact
Positive 49 (28.5) 23 (13.4) 
Negative 123 (71.5) 45 (26.2) 
Symptoms
Typical 121 (70.3) 49 (28.5) 
Non-speciﬁc 51 (29.7) 19 (11.0) 
Stage
Stage I 44 (25.6) 20 (11.6) 
Stage II 66 (38.4) 24 (14.0) 
Stage III 62 (36.0) 24 (14.0) 
Shunt, yes 79 (46.0) 38 (22.0) 
TST, tuberculin skin test; BCG, bacillus Calmette–Gue´rin.known/suspected case of TB); and 5–10 mm in children with close
contact with a known/suspected case of TB.2,3 Other causes of
meningitis were excluded in all cases by CSF tests including
bacterial culture, viral culture, fungal culture, and PCR for
enterovirus and herpes simplex virus.
Standard anti-TB therapy (isoniazid, rifampin, pyrazinamide,
streptomycin, or ethambutol) and other supportive measures
(steroids, anticonvulsants, and mannitol) were started for all
children with TBM. For this study, the typical symptoms of TBM in
children were regarded as fever, bulging fontanel, neck stiffness,
headache, vomiting, convulsions, and alteration of consciousness;
non-speciﬁc symptoms were regarded as abdominal pain, loss of
appetite, and growth retardation.
Children were divided into three different groups according to
their age: between 1 and 24 months (infant group), 24 and 72
months (early childhood), and 72 and 180 months.
2.1. Statistical analyses
All variables were compared for the three age groups. SPSS 10.0
for Windows (SPSS Inc., Chicago, IL, USA) was used for the data
entry and analysis. In the univariate analyses, the Chi-square test
was used for binary variables and the Student’s t-test for
continuous variables. Multivariable analysis using logistic regres-
sion was performed to assess predictors of mortality. Candidate
variables with either biological importance or a p-value of 0.2
were entered using a backwards, step-wise approach. A p-value of
0.05 was accepted as signiﬁcant.
3. Results
A total of 172 children with TBM were included in the study.
The mean age of the patients was 53.3  55.7 months (median 36
months, range 4–180 months). One hundred and nine (63.4%) of the
patients in the study were boys and the male/female ratio was 1.7.
Sixty-eight cases (39.5%) were aged between 1 and 24 months, 64
(37.2%) between 24 and 72 months, and 40 (48.1%) between 72 and
180 months. The gender distribution was similar in all groups.
Ninety-one of the patients were from urban areas (52.9%). On
admission, 44 of the patients (25.6%) were in stage I. The majority
of cases (70.4%) had typical TBM symptoms on admission, which
were similar in all age groups (p = 0.152). The TST was performed in24–72 months
n (%)
72–180 months
n (%)
p-Value
45 (26.2) 23 (21.1) 0.333
32 (18.6) 18 (10.5) 0.840
10 (5.8) 5 (2.9) 0.245
47(27.3) 29 (16.9)
7 (4.1) 6 (3.5)
10 (5.8) 10 (5.8) 0.488
48 (27.9) 26 (15.1)
6 (3.5) 4 (2.3)
16 (9.3) 10 (5.8) 0.456
48 (27.9) 30 (17.4)
40 (23.3) 32 (18.6) 0.152
24 (14.0) 8 (4.7)
12 (7.0) 12 (7.0) 0.447
25 (14.5) 17 (9.9)
27 (15.7) 11 (6.4)
27 (15.7) 14 (8.1) 0.082
Table 2
The relationships between radiological ﬁndings and the age groups.
All patients (N = 172)
n (%)
1–24 months
n (%)
24–72 months
n (%)
72–180 months
n (%)
p-Value
CT
Hydrocephaly 118 (68.6) 49 (28.4) 42 (24.4) 27 (15.7) 0.843
Parenchymal involvement 13 (7.6) 4 (2.3) 6 (3.5) 3 (1.8)
Basilar involvement 1 (0.6) 0 (0.0) 1 (0.6) 0 (0.0)
Tuberculoma 3 (1.8) 1 (0.6) 2 (1.2) 0 (0.0)
Normal 12 (7.0) 6 (3.5) 4 (2.3) 2 (1.2)
Chest X-ray
Hilar lymphadenopathy 10 (5.8) 2 (1.2) 8 (4.7) 0 (0.0) 0.009
Miliary 26 (15.1) 15 (8.8) 5 (3.0) 6 (3.5)
Pneumonia 19 (11.0) 9 (5.2) 7 (4.0) 3 (1.8)
Normal 97 (56.4) 42 (24.4) 44 (25.6) 31 (18.0)
CT, computed tomography.
Table 3
Factors associated with mortality in TBM cases
Alive, n (%) Dead, n (%) p-Value
TST
Positive 26 (15.1) 2 (1.2) 0.012
Negative 102 (59.3) 13 (7.6)
Absent 20 (11.6) 9 (5.2)
BCG
Positive 29 (16.9) 0 (0.0) 0.05
Negative 103 (59.9) 20 (11.6)
Absent 16 (9.3) 4 (2.3)
TBM, tuberculous meningitis; TST, tuberculin skin test; BCG, bacillus Calmette–
Gue´rin vaccination.
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vaccination data were available for 152 (88.4%) patients and 29
of them (19.1%) were positive. Domestic contact was identiﬁed in
BCG-negative cases (28.5%), half of which were infants (13.4%). No
recognized history of contact could be elicited for the other patients
(Table 1).
A CSF examination had been performed for diagnosis in all
cases. The mean CSF protein value was 103  124 mg/dl (median
72, range 1–700 mg/dl). In 97 cases (56.4%) the CSF protein level
was found to be >40 mg/dl. The mean CSF glucose value was
33.1  23.7 mg/dl (median 27, range 0.2–143 mg/dl). The CSF/
blood glucose ratio was <0.5 in 119 cases (69.8%). The mean
number of leukocytes was 371  775  106/l (median 170, range
10–5000  106/l; for eight of them it was 1000  106/l), and
lymphocyte dominance was found in 143 cases (83.1%). CSF PCR
examinations were performed on 21 CSF samples and all were
found negative for M. tuberculosis. Fasting gastric juice samples
were examined for AFB staining in 160 cases (93.0%); all of
them were reported as negative. Clinical samples were cultured
in 67 cases (39.0%) and M. tuberculosis was yielded in eight of
these samples (11.9%). None of these eight patients died; the
mortality rate was not signiﬁcantly different from that of culture-
negatives (p = 0.599). Bilirubin values were found to be >1 mg/dl in
30 cases and liver function tests were elevated in seven cases
(4.1%).
A CT examination was performed in 147 cases (85.5%). The
frequency of hydrocephalus, and of other CT ﬁndings, was similar
among the three age groups (p = 0.843). X-ray examinations were
found normal in 117 patients (68.0%). Chest X-ray examination
showed miliary involvement in 15 infants (22.1%). Miliary
involvement was found signiﬁcantly more often in the infant
age group than in the others (p = 0.009). Cases with hilar
lymphadenopathy as a clue for primary complex were more
frequent among younger patients; a total of 10 patients (5.8%)
showed hilar lymphadenopathy, and all of these cases were aged
less than 72 months (Table 2). Hydrocephalus was identiﬁed in 118
patients (68.6%) by CT examination. A shunt was placed in 79 cases
(45.9%). The mean duration of hospitalization was 17  4.2 days.
There was no difference among age groups. Seven of 39 (18.0%)
patients in stage I, nine of 71 (12.7%) patients in stage II, and eight of
62 (12.9%) patients in stage III died. There was no signiﬁcant
difference in mortality rate between the stages. In total, 24 patients
died in hospital.
When the factors possibly associated with mortality were
evaluated using multivariate analysis methods, BCG positivity
was found to be a preventive factor for mortality (p = 0.05).
The TST could not be performed in 20 (11.6%) patients. TST
negativity was a signiﬁcant factor for mortality (p = 0.012)
(Table 3).4. Discussion
This study shows that BCG vaccination protects from death and
that TST positivity is a useful marker to predict the prognosis of
TBM during childhood. The mortality rate in the BCG vaccinated
group was found to be zero. This result supports the concept that
the BCG vaccine provides protection against TBM and associated
mortality in the ﬁrst 2 years of life.
It is noteworthy that TBM was most common among infants
and those of the male sex. Meningoencephalitis associated with TB
more frequently occurs in infants younger than 2 years and
accounts for 5–10% of TB cases in this age group. This result
indicates that the severe forms of TB, such as miliary TB and
meningoencephalitis, may be observed with a greater possibility in
the infant age group. (Table 3)
Active TB infection develops more frequently in children who
have certain risk factors, such as malnutrition, steroid therapy,
immunodeﬁciency, and contact with an adult source.5,6 The
emergence of the disease is mainly dependent on cellular
immunocompetence and the presence of risk factors.7 A meta-
analysis on the protective effect of BCG vaccine in infants reported
a rate of protection of 50%,8 whereas another study suggested that
vaccination can only protect against the severe forms of TB
including TBM.9 Likewise, a ﬁfth of the cases in our study were
vaccinated against BCG. This study provides strong evidence of the
efﬁcacy of the BCG vaccination with regard to mortality in
childhood TBM. The results of previous studies have not been clear
about this protection.
This study showed that the mortality rate of cases with a
negative TST was greater than that for cases with a positive TST.
Previous studies have reported the importance of the TST in
eliciting real TB cases.10 Assessment of the TST in suspected TBM
cases contributes to the diagnostic process and to the prediction of
the prognosis. Although methods such as the TST may be helpful in
diagnosing latent TB cases in childhood, it may miss latent TB
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transition to active disease, as its sensitivity is not that high.11,12
The TST is a useful method to detect cases who have come into
contact with TB patients.13–15 The TST was negative in approxi-
mately two-thirds of our cases, while it could not be studied in a
minority of cases. The negative TST rate was found to be high in this
study, which indicates the necessity for a detailed assessment of
malnutrition, vaccination with live vaccine before the disease, or
factors leading to false TST negativity at the time of diagnosis.
The majority of the patients with TBM in the current study had a
normal chest X-ray. In this study, the rate of TBM accompanied by
mediastinal or hilar lymphadenopathy was lower than that
reported in previous studies. Also, the presence of miliary
involvement on chest X-ray in 22.1% of infant cases was
remarkable. Advances in imaging techniques including magnetic
resonance imaging (MRI) and ultrasonography also play a major
role in the diagnosis of TBM and other extrapulmonary TB.16 In
addition to hydrocephalus (68.6%), which was seen mainly in the
infant age group, and other pathological ﬁndings, cranial imaging
of our cases with TBM also revealed normal cranial imaging
ﬁndings in some cases. Chest X-rays play an important role in the
diagnosis of childhood TB. However cavities are more frequently
encountered in older children, such as adolescents.10 Changes on
chest X-rays may give some clues with regard to the primary focus
in extrapulmonary TB.17 While miliary TB was found to a great
extent in our infants with TBM, chest X-rays of the cases were
normal. It was noted that radiological ﬁndings have no utility in
predicting patient outcomes.
The most important route of transmission of TB in children is
domestic contact. As age increases, out-of-home contacts come to
the fore.4,18 It has been reported in the literature that 64% of
children with TB aged 1 to 15 years had a TB contact.19 Domestic
contact was reported in more than a quarter of our cases. This
considerably lower ﬁgure compared to contact rates reported in
the literature may have resulted from the low socioeconomic level
of the parents, environmental factors, or concealing the disease
due to social constraints.
As the patient histories were assessed retrospectively in our
study, the main limitation of this study is the shortcomings of the
patient histories. Due to these shortcomings, many parameters
were excluded from the study.
In conclusion, this study provides clear evidence that BCG
vaccination is effective in the prevention of TBM-associated
mortality. In addition, TST negativity may be considered as one
of the markers of a poor prognosis in patients with TBM.Conﬂict of interest: None declared.
References
1. Chatterjee S. Brain tuberculomas, tubercular meningitis, and post-tubercular
hydrocephalus in children. J Pediatr Neurosci 2011;6(Suppl 1):S96–100.
2. Brancusi F, Farrar J, Heemskerk D. Tuberculous meningitis in adults: a review of
a decade of developments focusing on prognostic factors for outcome. Future
Microbiol 2012;7:1101–16.
3. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, et al.
Efﬁcacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the
published literature. JAMA 1994;271:698–702.
4. Bourdin Trunz B, Fine PE, Dye C. Effect of BCG vaccination on childhood
tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis
and assessment of cost-effectiveness. Lancet 2006;367:1173–80.
5. Marais BJ, Gie RP, Schaaf HS, Hesseling AC, Obihara CC, Starke JJ, et al. The
natural history of childhood intra-thoracic tuberculosis: a critical review of
literature from the pre-chemotherapy era. Int J Tuberc Lung Dis 2004;8:392–
402.
6. Newton SM, Brent AJ, Anderson S, Whittaker E, Kampmann B. Paediatric
tuberculosis. Lancet Infect Dis 2008;8:498–510.
7. Rigouts L. Clinical practice: diagnosis of childhood tuberculosis. Eur J Pediatr
2009;168:1285–90.
8. Colditz GA, Berkey CS, Mosteller F, Brewer TF, Wilson ME, Burdick E, et al. The
efﬁcacy of bacillus Calmette–Gue´rin vaccination of newborns and infants in the
prevention of tuberculosis: meta-analyses of the published literature. Pediatrics
1995;96(1 Pt 1):29–35.
9. Wu¨nsch Filho V, de Castilho EA, Rodrigues LC, Huttly SR. Effectiveness of BCG
vaccination against tuberculous meningitis: a case-control study in Sa˜o Paulo,
Brazil. Bull World Health Organ 1990;68(1):69–74.
10. Shingadia D, Novelli V. Diagnosis and treatment of tuberculosis in children.
Lancet Infect Dis 2003;3:624–32.
11. Munoz FM, Starke JR. Childhood tuberculosis. In: Raviglione MC, editor.
Reichman and Hershﬁeld’s tuberculosis: a comprehensive, international approach.
USA: Informa Healthcare; 2006. p. 307–44.
12. Rehman A. Irfanullah. Interferon gamma assays for tuberculosis in children. J
Pak Med Assoc 2008;58:508–11.
13. Hill PC, Brookes RH, Adetifa IM, Fox A, Jackson-Sillah D, Lugos MD, et al.
Comparison of enzyme-linked immunospot assay and tuberculin skin test in
healthy children exposed to Mycobacterium tuberculosis. Pediatrics
2006;117:1542–8.
14. Connell TG, Ritz N, Paxton GA, Buttery JP, Curtis N, Ranganathan SC. A three-
way comparison of tuberculin skin testing, QuantiFERON-TB gold and T-SPOT.
TB in children PLoS One 2008;3:e2624.
15. Mandalakas AM, Hesseling AC, Chegou NN, Kirchner HL, Zhu X, Marais BJ, et al.
High level of discordant IGRA results in HIV infected adults and children. Int J
Tuberc Lung Dis 2008;12:417–23.
16. Andronikou S, Wieselthaler N. Modern imaging of tuberculosis in children:
thoracic, central nervous system and abdominal tuberculosis. Pediatr Radiol
2004;34:861–75.
17. Basu S, Ganguly S, Chandra PK, Basu S. Clinical proﬁle and outcome of abdomi-
nal tuberculosis in Indian children. Singapore Med J 2007;48:900–5.
18. Marais BJ, Pai M. Recent advances in the diagnosis of childhood tuberculosis.
Arch Dis Child 2007;92:446–52.
19. Franco R, Santana MA, Matos E, Sousa V, Lemos AC. Clinical and radiological
analysis of children and adolescents with tuberculosis in Bahia, Brazil. Braz J
Infect Dis 2003;7:73–81.
